Your browser doesn't support javascript.
loading
Italian Guidelines for the Management of Sporadic Primary Hyperparathyroidism.
Vescini, Fabio; Borretta, Giorgio; Chiodini, Iacopo; Boniardi, Marco; Carotti, Marina; Castellano, Elena; Cipriani, Cristiana; Eller-Vainicher, Cristina; Giannini, Sandro; Iacobone, Maurizio; Salcuni, Antonio Stefano; Saponaro, Federica; Spiezia, Stefano; Versari, Annibale; Zavatta, Guido; Mitrova, Zuzana; Saulle, Rosella; Vecchi, Simona; Antonini, Debora; Basile, Michele; Giovanazzi, Alexia; Paoletta, Agostino; Papini, Enrico; Persichetti, Agnese; Samperi, Irene; Scoppola, Alessandro; Novizio, Roberto; Calò, Pietro Giorgio; Cetani, Filomena; Cianferotti, Luisella; Corbetta, Sabrina; De Rimini, Maria Luisa; Falchetti, Alberto; Iannetti, Giovanni; Laureti, Stefano; Lombardi, Celestino Pio; Madeo, Bruno; Marcocci, Claudio; Mazzaferro, Sandro; Miele, Vittorio; Minisola, Salvatore; Palermo, Andrea; Pepe, Jessica; Scillitani, Alfredo; Tonzar, Laura; Grimaldi, Franco; Cozzi, Renato; Attanasio, Roberto.
Affiliation
  • Vescini F; Endocrinology Unit, Azienda Sanitaria-Universitaria Friuli Centrale, P.O. Santa Maria della Misericordia, Udine, Italy.
  • Borretta G; Department of Endocrinology, Diabetes and Metabolism, Ospedale Santa Croce and Carle Hospital, Cuneo, Italy.
  • Chiodini I; Endocrinology Department, ASST Grande Ospedale Metropolitano di Niguarda, Milan, Italy.
  • Boniardi M; Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
  • Carotti M; Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
  • Castellano E; General Oncologic and Mini-invasive Surgery Department, ASST Grande Ospedale Metropolitano di Niguarda, Milan, Italy.
  • Cipriani C; Department of Radiology, AOU delle Marche, Ancona, Università Politecnica delle Marche, Ancona, Italy.
  • Eller-Vainicher C; Department of Endocrinology, Diabetes and Metabolism, Ospedale Santa Croce and Carle Hospital, Cuneo, Italy.
  • Giannini S; Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Iacobone M; Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Salcuni AS; Clinica Medica 1, Department of Medicine, University of Padova, Padova, Italy.
  • Saponaro F; Endocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
  • Spiezia S; Endocrinology Unit, Azienda Sanitaria-Universitaria Friuli Centrale, P.O. Santa Maria della Misericordia, Udine, Italy.
  • Versari A; Department of Surgical, Medical, and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
  • Zavatta G; Department of Endocrine and Ultrasound-Guided Surgery, Ospedale del Mare, Naples, Italy.
  • Mitrova Z; Nuclear Medicine Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.
  • Saulle R; Division of Endocrinology and Diabetes Prevention and Care, IRCCS AOU di Bologna, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Vecchi S; Department of Epidemiology, Lazio Region Health Service, Rome, Italy.
  • Antonini D; Department of Epidemiology, Lazio Region Health Service, Rome, Italy.
  • Basile M; Department of Epidemiology, Lazio Region Health Service, Rome, Italy.
  • Giovanazzi A; High School of Economy and Management of Health Systems, Catholic University of Sacred Heart, Rome, Italy.
  • Paoletta A; High School of Economy and Management of Health Systems, Catholic University of Sacred Heart, Rome, Italy.
  • Papini E; Azienda Provinciale per i Servizi Sanitari della Provincia Autonoma di Trento, Trento, Italy.
  • Persichetti A; Department of Endocrinology, ULSS6 Euganea, Padova, Italy.
  • Samperi I; Endocrinology, Ospedale Regina Apostolorum, Albano Laziale, Italy.
  • Scoppola A; Ministry of Interior - Department of Firefighters, Public Rescue and Civil Defense, Rome, Italy.
  • Novizio R; Endocrinology, ASL Novara, Italy.
  • Calò PG; Endocrinology, Ospedale Santo Spirito, Rome, Italy.
  • Cetani F; Endocrinology and Metabolism, Agostino Gemelli University Polyclinic (IRCCS), Catholic University of the Sacred Heart, Rome, Italy.
  • Cianferotti L; SIUEC President, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
  • Corbetta S; Endocrine Unit 2, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • De Rimini ML; Bone Metabolic Diseases Unit, Department of Experimental, Clinical and Biomedical Sciences, University of Florence, AOU Careggi, Florence, Italy.
  • Falchetti A; Bone Metabolism and Diabetes, IRCCS Istituto Auxologico Italiano, Milan, Italy.
  • Iannetti G; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
  • Laureti S; AIMN President, Nuclear Medicine Unit, AORN Ospedali dei Colli, Naples, Italy.
  • Lombardi CP; Laboratory of Experimental Clinical Research on Bone Metabolism, Istituto Auxologico Italiano IRCCS, Milan, Italy.
  • Madeo B; SIUMB President, Ultrasound Unit, S. Spirito Hospital, Pescara, Italy.
  • Marcocci C; General Practitioner, USL Umbria 1, Perugia, Italy.
  • Mazzaferro S; Endocrine Surgery, Ospedale Gemelli, Rome, Italy.
  • Miele V; Unit of Endocrinology, Department of Medical Specialties, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria di Modena, Italy.
  • Minisola S; Endocrine Unit 2, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Palermo A; Nephrology Unit at Policlinico Umberto I Hospital and Department of Translation and Precision Medicine, Sapienza University of Rome, Italy.
  • Pepe J; Department of Emergency Radiology, Careggi University Hospital, Florence, Baggiovara, Italy.
  • Scillitani A; UOC Medicina Interna A, Malattie Metaboliche dell'Osso, Ambulatorio Osteoporosi e Osteopatie Fragilizzanti, Sapienza University of Rome, Rome Italy.
  • Tonzar L; Unit of Thyroid and Bone-Metabolic Diseases, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Grimaldi F; Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Cozzi R; Unit of Endocrinology, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy.
  • Attanasio R; Endocrinology Unit, Azienda Sanitaria-Universitaria Friuli Centrale, P.O. Santa Maria della Misericordia, Udine, Italy.
Article in En | MEDLINE | ID: mdl-38644730
ABSTRACT

AIM:

This guideline (GL) is aimed at providing a clinical practice reference for the management of sporadic primary hyperparathyroidism (PHPT) in adults. PHPT management in pregnancy was not considered.

METHODS:

This GL has been developed following the methods described in the Manual of the Italian National Guideline System. For each question, the panel appointed by Associazione Medici Endocrinology (AME) and Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (SIOMMMS) identified potentially relevant outcomes, which were then rated for their impact on therapeutic choices. Only outcomes classified as "critical" and "important" were considered in the systematic review of evidence. Those classified as "critical" were considered for the clinical practice recommendations.

RESULTS:

The present GL provides recommendations about the roles of pharmacological and surgical treatment for the clinical management of sporadic PHPT. Parathyroidectomy is recommended in comparison to surveillance or pharmacologic treatment in any adult (outside of pregnancy) or elderly subject diagnosed with sporadic PHPT who is symptomatic or meets any of the following criteria • Serum calcium levels >1 mg/dL above the upper limit of normal range. • Urinary calcium levels >4 mg/kg/day. • Osteoporosis disclosed by DXA examination and/or any fragility fracture. • Renal function impairment (eGFR <60 mL/min). • Clinic or silent nephrolithiasis. • Age ≤50 years. Monitoring and treatment of any comorbidity or complication of PHPT at bone, kidney, or cardiovascular level are suggested for patients who do not meet the criteria for surgery or are not operated on for any reason. Sixteen indications for good clinical practice are provided in addition to the recommendations.

CONCLUSION:

The present GL is directed to endocrinologists and surgeons - working in hospitals, territorial services or private practice - and to general practitioners and patients. The recommendations should also consider the patient's preferences and the available resources and expertise.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hyperparathyroidism, Primary Limits: Adult / Female / Humans Country/Region as subject: Europa Language: En Journal: Endocr Metab Immune Disord Drug Targets Journal subject: ALERGIA E IMUNOLOGIA / ENDOCRINOLOGIA / METABOLISMO / TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hyperparathyroidism, Primary Limits: Adult / Female / Humans Country/Region as subject: Europa Language: En Journal: Endocr Metab Immune Disord Drug Targets Journal subject: ALERGIA E IMUNOLOGIA / ENDOCRINOLOGIA / METABOLISMO / TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: